Furthermore, pretreatment with gemcitabine or cyclophosphamide, chemotherapies that induce ICD, increased iNKT cell immunotherapy efficacy and survival in an in vivo 4T1 breast cancer model, although tumor-targeted NK and CD8 T cell responses were not higher than with NKT cell activation alone [172]. This evidence concerns the gene CD8A and neoplasm.